Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist: Implications for Cardiovascular Disease in Patients with Diabetes Mellitus

Author： Cavender Matthew A.   Lincoff A. Michael  

Publisher： Adis International

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.10, Iss.4, 2010-08, pp. : 209-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

By Foley-Comer Adam J   Young Anne-Marie   Russell-Yarde Fiona   Jordan Paul  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 1, 2011-01 ,pp. : 3-12

Informa Healthcare

Access to resources Recommend Favorite

A Dual PPAR α/γ Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects

By Decochez Katelijn  

Drugs in R&D, Vol. 7, Iss. 2, 2006-01 ,pp. : 99-110

Adis International

Access to resources Recommend Favorite

New Pharmacological Perspectives and Therapeutic Potential of PPAR-&ggr; Agonists

By  

Current Pharmaceutical Design, Vol. 10, Iss. 28, 2004-11 ,pp. : 3505-3524

Bentham Science Publishers

Access to resources Recommend Favorite

PPAR-γ: Therapeutic Prospects in Parkinson's Disease

By  

Current Drug Targets, Vol. 14, Iss. 7, 2013-06 ,pp. : 743-751

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Potential of Copper Chelation with Triethylenetetramine in Managing Diabetes Mellitus and Alzheimer's Disease

By Cooper Garth J.S.  

Drugs, Vol. 71, Iss. 10, 2011-07 ,pp. : 1281-1320

Adis International

Access to resources Recommend Favorite